Tuberculosis Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Metronidazole Combined With Antituberculous Chemotherapy vs. Antituberculous Chemotherapy With Placebo in Subjects With Multi-Drug Resistant Pulmonary Tuberculosis
This study will evaluate the effect of adding metronidazole to standard second-line therapy
for tuberculosis in patients who have multi-drug resistant tuberculosis (MDR-TB) of the
lungs. It will evaluate the safety and tolerability of metronidazole in combination with
antituberculosis agents. Metronidazole is a drug widely used to treat bacterial and
parasitic infections occurring in environments with very little oxygen such as the human
colon. Nine million new cases of sputum-positive tuberculosis are diagnosed worldwide each
year.
Patients ages 20 and older who have symptoms of TB, who have been treated for tuberculosis
but whose disease is multi-drug resistant, and who are not pregnant or breast feeding may be
eligible for this study. They will be recruited in the National Masan Tuberculosis Hospital
(NMTH), Masan, Republic of Korea. Patients will undergo the following tests and procedures:
- Collection of sputum for counting of bacteria.
- Drawing of blood for routine blood chemistry analysis; for measuring levels of
metronidazole; TB lipid analysis; and for testing levels of T-cells, which are part of
an immune response.
- Two targeted positron emission tomography (PET) scans, each with a computed tomography
(CT) scan, and five high-resolution CT scans.
Patients will receive either an 8-week course of standard second-line agents plus placebo
(sugar pill) or an 8-week course of standard agents plus metronidazole. The subjects,
doctors and researchers will not know which patients are taking the metronidazole until
after the first 2 years of the trial. A total of 60 patients will be assigned to two cohorts
of 30 patients each. After 8 weeks, all patients will return to the standard of care
chemotherapy, according to normal procedures at NMTH.
Side effects of metronidazole commonly reported are vaginal discharge, symptoms of Candida
cervicitis and vaginitis, headache, nausea and vomiting, and dizziness. Peripheral
neuropathy, an abnormal condition of the nerves, may also be a side effect. The precise
incidence of neuropathy is unknown but is usually related to the duration of metronidazole
use. It can almost always be reversed when the drug is discontinued. Serious side effects,
though rare, may include leukopenia and thrombocytopenia (disorders in the blood), seizures
and other central nervous system problems, and hepatitis.
This study may or may not have a direct benefit for participants. However, it is possible
that patients' drug-resistant disease may be more effectively treated as a result of
metronidazole. The study may help identify new methods for measuring drug effectiveness
during TB studies.
Status | Completed |
Enrollment | 35 |
Est. completion date | February 2013 |
Est. primary completion date | October 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
- INCLUSION CRITERIA: 1. Male and females age 20 and above 2. Signs or symptoms of tuberculosis (i.e., cough that has lasted 3 weeks or longer, hemoptysis, chest pain, fatigue, weight loss, night sweats) 3. Subjects with documented AFB smear-positive pulmonary tuberculosis at screening to NMTH 4. Radiographic evidence of tuberculous disease of the lung(s) 5. TB isolate resistant to at least isoniazid and rifampicin 6. Drug Susceptibility Testing (DST) results known for ofloxacin (can be either sensitive or resistant) 7. Ability and willingness to give written or oral informed consent 8. Willingness to be an inpatient at NMTH for, at minimum, the duration of study drug/placebo treatment 9. Willingness to have samples stored 10. Available for follow-up visits EXCLUSION CRITERIA: 1. People who are unwilling or unable to abstain from alcohol consumption for the study drug treatment duration (8 weeks) 2. Women of childbearing potential, who are pregnant, breast feeding, or unwilling to avoid pregnancy by the use of appropriate contraception including oral and subcutaneous implantable hormonal contraceptives, condoms, diaphragm, intrauterine device (IUD), or abstinence from sexual intercourse at study screening and during the study drug/placebo treatment (two months with allowed stops) (Note: Prospective female participants of childbearing potential must have negative pregnancy test (urine) within 48 hours prior to study entry.) 3. Subjects with pan resistant isolates 4. Presently taking 2nd -line agents started more than 14 days prior to initial FDG-PET scan 5. People with any of the following in their current medical assessment: 1. Absolute neutrophil count less than 1000 cells/mL 2. White Blood Cell count (WBC) less than 3.0 X 10(3)/microliter 3. Hemoglobin less than 7.0 g/dL 4. Platelet count less than 75,000 cells/mm(3) 5. Serum creatinine greater than 2.0 mg/dL 6. Aspartate aminotransferase (AST or SGOT) greater than 100 IU/L 7. Alanine aminotransferase (ALT or SGPT) greater than 100 IU/L 8. Total bilirubin greater than 2 mg/dL 9. Moderate or severe peripheral neuropathy 10. HIV-1 or HIV-2 infection 11. History of systemic lupus erythematosus, rheumatoid arthritis, or other connective tissue disease 6. Terminal illness with impending mortality 7. History of allergy or serious adverse reaction to metronidazole or placebo formulation used in this study 8. The use of any of the following drugs within 30 days prior to study or anticipated use of these drugs within the next 60 days: 1. Systemic cancer chemotherapy 2. Systemic corticosteroids 3. Systemic investigational agents 4. Antiretroviral medications 5. Growth factors 6. HIV vaccines 7. Immune globulin 8. Interleukins 9. Interferons 9. The need for ongoing therapy with warfarin, phenytoin, lithium, cimetidine, disulfiram, ergot derivatives, cholestyramine, fosphenytoin, carbamazepine, cyclosporine, tacrolimus, sirolimus, amiodarone or phenobarbital while on study drug. 10. Any other serious systemic illness requiring treatment and/or hospitalization until subject either completes therapy or is clinically stable on therapy for at least 14 days prior to study entry 11. Unwilling to be an inpatient at NMTH for greater than or equal to 2 months 12. Any condition that the investigator believes would warrant exclusion |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | National Masan Tuberculosis Hospital | Masan | |
Korea, Republic of | Yonsei University College of Medicine | Seoul |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
Korea, Republic of,
Andreu J, Cáceres J, Pallisa E, Martinez-Rodriguez M. Radiological manifestations of pulmonary tuberculosis. Eur J Radiol. 2004 Aug;51(2):139-49. — View Citation
Brooks JV, Furney SK, Orme IM. Metronidazole therapy in mice infected with tuberculosis. Antimicrob Agents Chemother. 1999 May;43(5):1285-8. — View Citation
Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis. 2004 Mar 1;38(5):754-6. Epub 2004 Feb 17. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in TB Lesion Sizes Using High Resolution Computed Tomography (HRCT). | Lesions were defined as nodules (<2 mm, 2-<4 mm, and 4-10 mm), consolidations, collapse, cavities, fibrosis, bronchial thickening, tree-in-bud opacities, and ground glass opacities. Each CT was divided into six zones (upper, middle, and lower zones of the right and left lungs) and independently scored for the above lesions by three separate radiologists blinded to treatment arm. A fourth radiologist adjudicated any scores that were widely discrepant among the initial three radiologists. The HRCT score was determined by visually estimating the extent of the above lesions in each lung zone as follows: 0=0% involvement; 1= 1-25% involvement; 2=26-50% involvement; 3=51-75% involvement; and 4=76-100% involvement. A composite score for each lesion was calculated by adding the score for each specific abnormality in the 6 lung zones and dividing by 6, with the change in composite score measured at 2 and 6 months compared to baseline. Composite sums of all 10 composite scores are reported. | 6 months. | No |
Secondary | Time to Sputum Culture Conversion to Negative on Solid Medium | 2 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |